<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198792</url>
  </required_header>
  <id_info>
    <org_study_id>GES</org_study_id>
    <nct_id>NCT04198792</nct_id>
  </id_info>
  <brief_title>Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients</brief_title>
  <official_title>Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients with refractory cardiac arrest can be saved by ECMO-treatment. However&#xD;
      predictors defining which patients can be saved, and not, is missing. This shall be evaluated&#xD;
      together with neurological prognostic factors during ECMO treatment. Long term cognitive&#xD;
      function will be evaluated by physical examination and standardized tests in survivors. Costs&#xD;
      will be assessed. Infection rates in patients will be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      75-80% of patients with cardiac arrest don't survive. Some of those, who despite advanced&#xD;
      cardiopulmonary resuscitation don't get their circulation back, can be saved by&#xD;
      ECMO-treatment. This is called E-CPR. In E-CPR the selection of patients is of uttermost&#xD;
      importance. Despite this good selection criteria are missing.&#xD;
&#xD;
      ECMO-treatment it self is also associated with severe morbidity and high mortality, where&#xD;
      long term evaluation of cognitive function is missing.&#xD;
&#xD;
      In ECPR patients, pre arrest factors as well as measurable circulatory and other prognostic&#xD;
      factors are measured during ECPR. Circulatory effect during ECPR is measured by end tidal&#xD;
      carbon dioxide, NIRS-brain, pupil diameter, spontaneous movement, spontaneous breathing,&#xD;
      serum lactate and lactate increase during CPR.&#xD;
&#xD;
      All ECMO-treated patients at Sahlgrenska University hospital since 2010 are included. In&#xD;
      December 2015 local selection guidelines for ECPR-initiation was created based on the&#xD;
      literature and our early cohort. Those guidelines are evaluated in our 2016-2018 cohort with&#xD;
      survival in good neurological status as outcome.&#xD;
&#xD;
      Neurological prognostication according to European Guidelines of post cardiac arrest care is&#xD;
      done, including early CT-scan of the brain, S-NSE, S100B, EEG, assessment of myoclonic status&#xD;
      and pupil and corneal reflexes. The general CPR guidelines accuracy for survival with good&#xD;
      neurological outcome in ECPR patients is tested.&#xD;
&#xD;
      Both ECPR and ECMO-patients without previous CPR will have a long term follow up with&#xD;
      standardized questionnaires (CPC, MRS, Mocca, Trailmaking test, MQ-5D, SF36, etc) and&#xD;
      physiological and motor tests. Qualy will be calculated.&#xD;
&#xD;
      The cost of the treatment in hospital will be assessed.&#xD;
&#xD;
      The infection rate in all ECMO-patients from 2004- will be evaluated by blood and airway&#xD;
      Cultures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival with Cerebral Performance Category 1 or 2.</measure>
    <time_frame>1 year</time_frame>
    <description>Good neurological outcome in ECPR-patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physicians Global Assessment to measure quality of life</measure>
    <time_frame>1-7 year</time_frame>
    <description>Quality of Life in survivors after ECPR and ECMO without cardiac arrest, Measured with in depth interviews</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive blood Cultures</measure>
    <time_frame>1 month</time_frame>
    <description>Infection rates in ECMO-patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euro Qualy - 5 dimension (EQ-5D)</measure>
    <time_frame>1-7 years</time_frame>
    <description>Assesment of quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral Performance Scale (CPC)</measure>
    <time_frame>1-7 years</time_frame>
    <description>Assessment of cerebral performance. 1-5, where 1-2 is considered good outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Rankin scale (MRs)</measure>
    <time_frame>1-7 years</time_frame>
    <description>Assessmenty of cognitive function. 0-6, where 0 is best.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trailmaking test</measure>
    <time_frame>1-7 years</time_frame>
    <description>Assessmenty of cognitive function. Shorter time is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form -36 (SF-36)</measure>
    <time_frame>1-7 years</time_frame>
    <description>Quality of life. 8 scaled scores from 0-100, where 100 is best.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New York heart association class (NYHA class)</measure>
    <time_frame>1-7 years</time_frame>
    <description>Assessment of physical function.1-4, where 1 is best</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cost</measure>
    <time_frame>3 month</time_frame>
    <description>The in hospital cost of the treatment for the patients, in Swedish kronor.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <condition>Hypoxia-Ischemia, Brain</condition>
  <arm_group>
    <arm_group_label>ECPR patients</arm_group_label>
    <description>Patients that is put om ECMO during cardiac arrest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECMO patients, non-ECPR</arm_group_label>
    <description>Patients that is put on ECMO due to circulatory failure but not cardiac arrest</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest</description>
    <arm_group_label>ECMO patients, non-ECPR</arm_group_label>
    <arm_group_label>ECPR patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ECPR Group: Patients who is put on ECMO during cardiac arrest. ECMO Group: Patients who is&#xD;
        put on ECMO with some ongoing circulaiton&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECMO-treated patients att Sahlgrenska University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Redfors, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sahlgrenska Academy ar Sahlgrenska University Hospital, Gorhenburg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bengt Redfors, MD, PhD</last_name>
    <phone>+46768445402</phone>
    <email>bengt.redfors@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anders Byttner, MD</last_name>
    <phone>+46703227966</phone>
    <email>anders.byttner@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska Akademy at Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Redfors, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Bengt Redfors</investigator_full_name>
    <investigator_title>MD, PhD, Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

